Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Bayer Low Dose Ads Urge Consumers To “Do More” In Cardiac Prevention

This article was originally published in The Tan Sheet

Executive Summary

Bayer seeks to increase consumer awareness of low-dose aspirin for primary prevention of heart attacks in a television spot that broke June 23

You may also be interested in...



Bayer Seeks To Reinvigorate Aspirin’s Pain Relief Profile

Bayer HealthCare recently launched its “Fast Relief Challenge” campaign to remind consumers about aspirin’s pain relief indication and to highlight Bayer Advanced Aspirin. The firm refers to a survey showing 8% of respondents preferred aspirin more than other OTC pain relievers.

Bayer Seeks To Reinvigorate Aspirin’s Pain Relief Profile

Bayer HealthCare recently launched its “Fast Relief Challenge” campaign to remind consumers about aspirin’s pain relief indication and to highlight Bayer Advanced Aspirin. The firm refers to a survey showing 8% of respondents preferred aspirin more than other OTC pain relievers.

Aspirin For MI Primary Prevention Indication Needs More Study, Panel Says

A long-term randomized prospective trial of at least 15,000 patients would be needed to adequately support professional aspirin labeling on primary prevention of myocardial infarction, according to members of FDA's Cardiovascular & Renal Drugs Advisory committee

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS098371

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel